Indian Army Denosumab 60 mg/ml, Insulin Lispro, Triptorelin 11.25mg, Cabozantinib 20mg Tender 2026

Bidders must submit a compliance sheet, a valid CDSCO/DCGI drug license, NABL batch test certificates, and OEM authorization details. Include the EMD of ₹27,255 and 6-item BOQ alignment. Ensure the batch testing documents are current and the manufacturer authorization specifies contact details and product scope.

Required documents include: GST registration, PAN, CDSCO/DCGI license for each drug, OEM authorization, NABL batch test certificates, notarized undertaking, and the compliance sheet with MRP and MFG details. Ensure batch certificates accompany supply during any delivery.

Delivery starts from the last date of the original delivery order; if quantity increases by up to 25%, extended time is calculated as (additional quantity/original quantity) × original delivery period, with a minimum of 30 days. All items must meet QA benchmarks and pricing ceilings.

The EMD is ₹27,255, submitted as per standard government tender formats. It is intended to secure bid integrity and is typically refundable after contract finalization or after bid evaluation per guidelines.

Bidders must provide batch test certificates from NABL-accredited laboratories or government authorities to verify quality. Certificates should cover batch provenance, potency, sterility, and compliance with central/state government pricing ceilings.

Authorized distributors must submit an OEM authorization form detailing name, designation, address, email, and phone number. The authorization confirms product eligibility, warranty coverage, and post-sales support for Denosumab, Insulin Lispro, Cabozantinib, and related drugs.

The tender covers Denosumab 60 mg/ml injections, Insulin Lispro formulations, Triptorelin 11.25 mg injections, Cabozantinib 20 mg tablets, Relugolix 120 mg tablets, and Human Insulin injections, with six items in total and item-specific requirements in the final BOQ.